How is Vantrela ER formulated to be abuse deterrent?

Vantrela ER (hydrocodone bitartrate) uses Teva's proprietary abuse-deterrent technology based on a multi-layer gel-forming polymer coating that regulates drug release.

What is Vantrela ER?

Vantrela ER (hydrocodone) is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Vantrela ER is formulated as extended-release tablets. It is a Schedule II controlled substance with a high potential for abuse and and dependence.

How is Vantrela ER Abuse-Deterrent?

Vantrela ER is formulated with physicochemical properties intended to make the tablet more difficult to manipulate. A multi-layer gel-forming polymer coating regulates drug release.

Vantrela ER resists crushing, breaking, and dissolution using a variety of tools and solvents and still retains some extended-release properties despite manipulation.

Vantrela ER will become viscous when crushed and dissolved in liquid, making injection difficult.

The abuse-deterrent properties of Vantrela ER are expected to reduce, but not totally prevent, oral, intranasal and intravenous abuse of the drug when the tablets are manipulated.